Trial reportDiabetes, metabolic syndrome and obesity : targets and therapy2026
Efficacy of Hongjing Qiwei Formula Combined with Tadalafil in the Treatment of Erectile Dysfunction Associated with Type 2 Diabetes Mellitus: A Double-Blind, Single-Dummy, Randomized Controlled Trial.
Trial report in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Erectile dysfunction associated with diabetes mellitus (DMED) is common and may respond inadequately to phosphodiesterase type 5 inhibitor therapy. Evidence regarding traditional Chinese medicine combined with tadalafil for DMED remains limited. This study evaluated the efficacy and safety of Hongjing Qiwei Formula (HJQWF) plus tadalafil in patients with type 2 DMED. Methods: In this double-blind, single-dummy, randomized controlled trial, 76 participants were randomly assigned in a 1:1 ratio to receive HJQWF plus tadalafil 5 mg (treatment group) once daily or matched HJQWF placebo plus tadalafil 5 mg (control group) once daily for 6 weeks, followed by a 4-week post-treatment follow-up. The primary outcome was the International Index of Erectile Function-5 (IIEF-5). Secondary outcomes included erection hardness score (EHS), Traditional Chinese Medicine syndrome score (TCMSS), Sexual Encounter Profile Questions 2 and 3 (SEP-2 and SEP-3), and safety outcomes. Results: Seventy-one participants completed the intervention (treatment group, n = 36; control group, n = 35). At week 6, the mean change in IIEF-5 from baseline was greater in the treatment group than in the control group (5.53 ± 3.81 vs 3.26 ± 3.89; P < 0.05). The corresponding improvement in EHS was also greater with HJQWF (0.92 ± 0.84 vs 0.46 ± 0.70; P < 0.05). TCMSS decreased more markedly in the treatment group than in the control group (-16.14 ± 5.32 vs -2.77 ± 4.60; P < 0.05). At week 6, the proportion of participants reporting successful intercourse on SEP-3 was higher in the treatment group than in the control group (72.22% vs 45.71%; P < 0.05). No serious adverse events or clinically significant laboratory abnormalities were reported. Conclusion: HJQWF added to tadalafil may provide additional short-term improvement in erectile-function outcomes in men with type 2 DMED, and can still continuously improve erectile function even four weeks after discontinuation with no major safety signal observed during the study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.